Oligonucleotide Therapeutics Market Size, Growth, Share & Trends Analysis
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles. The focus remains on enhanced potency, stability, and selectivity, which is fueling interest in next-generation modifications.
KEY TAKEAWAYS
-
By RegionThe North America oligonucleotide synthesis market accounted for a 45.6% revenue share in 2024.
-
By MoleculeThe nusinersen segment dominated the market in 2024 with a share of 26.5%.
-
By TypeThe antisense oligonucleotide-based drugs segment dominated the market in 2024 with a share of 61.2%.
-
By Route of AdministrationThe subcutaneous segment dominated the market in 2024 with a share of 58.0%.
-
By Disease typeThe neurological disorders segment dominated the market in 2024.
-
Competitive LandscapeBiogen and Alnylam Pharmaceuticals, Inc. were identified as the key players in the oligonucleotide therapeutics market, given their strong market share and product footprint.
-
Competitive LandscapeAvidity Biosciences and Argo Biopharma, among others, have distinguished themselves among start-ups and SMEs by securing strong footholds in niche areas, underscoring their potential as emerging market leaders.
The oligonucleotide therapeutics market is growing due to increased adoption of ASO and siRNA drugs and a steady pipeline of late-stage clinical programs. Pharma and biotech companies are boosting orders for high-purity therapeutic oligonucleotides, including custom sequences, modified backbones, and conjugated formats to enhance targeting and dosing durability. Demand is also driven by gene editing advancements, where guide RNA design and optimization are creating additional need for advanced oligo capabilities.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The oligonucleotide therapeutics market is driven by the rapid shift toward RNA-based drugs and the adoption of molecular decision-making in the pharmaceutical industry. Pharma companies are advancing their pipelines for ASO and siRNA. This has resulted in increased demand for highly pure and precise oligonucleotides, with low levels of impurities. End users are prioritizing quality, safety, and regulatory compliance as programs move from clinical development to the next stages of commercialization.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Increasing use of synthesized oligonucleotides in therapeutic and diagnostic applications
-
Ongoing technological advancements
Level
-
Complexities associated with therapeutic oligonucleotides
Level
-
Rising R&D investments by key players in emerging economies
Level
-
Lack of standard regulations
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing use of synthesized oligonucleotides in therapeutic and diagnostic applications
A key factor driving the growth of the oligonucleotide therapeutics market is the increasing adoption of oligonucleotides in various therapeutic and diagnostic applications. While oligonucleotides form the foundation of ASO and siRNA drugs, creating demand for high-purity, customized sequences, diagnostics also heavily rely on synthesized oligonucleotides for PCR, qPCR, NGS, and molecular assays. The rising use of precision medicine and liquid biopsy procedures is further boosting overall volume growth. This dual demand from drugs and diagnostics has led to high utilization at both development and commercial levels.
Restraint: Complexities associated with therapeutic oligonucleotides
The growth of therapeutic oligonucleotides is often limited by their inherent complexities. Such molecules require precise sequence design, advanced chemical modifications, and strict purity control. Their production and testing procedures are more complex than those for many small molecules. Delivering these molecules to the target tissues and achieving endosomal escape (release from cell compartments) are additional challenges. These factors increase the risk, cost, and development time, thereby hindering broader acceptance of these therapies.
Opportunity: Rising R&D investments by key players in emerging economies
Rising R&D spending by major players in emerging economies presents a significant opportunity for strong growth. Pharma and biotech companies in Asia and other developing regions are expanding their RNA therapeutics pipelines. Additionally, governments support local innovators by providing grants and establishing facilities. This helps develop local skills in oligo synthesis, analytics, and GMP manufacturing. As a result, it reduces dependence on Western vendors and opens new markets for therapeutic oligonucleotides.
Challenge: Lack of standard regulations
The lack of universal regulations remains the main challenge in the global oligonucleotide therapeutics market. Oligonucleotides are intermediates between small molecules and biologics, and regulatory frameworks have not been fully harmonized across different regions. Expectations in CMC, impurity profiling, and analytical characterization may differ not only between agencies but also among review divisions. This poses risks for developers in designing development plans and scaling manufacturing processes.
OLIGONUCLEOTIDE THERAPEUTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
During the COVID-19 testing scale-up, the CDC’s EUA diagnostic panel relied on oligonucleotide primers and probes as core reagents. IDT supplied primer/probe mixes aligned to CDC assay sequences and continued to offer equivalent RUO kits. | Enabled fast ramp of primer/probe availability for high-throughput testing workflows |Supported broader lab adoption by making critical oligonucleotides easier to source and standardize. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The oligonucleotide therapeutics market ecosystem covers the entire supply chain, from raw materials to commercial drug production. Upstream, it includes suppliers of essential synthesis inputs such as phosphoramidites, solid supports (CPG), activators, oxidizers, deblocking reagents, and high-purity solvents. It also encompasses synthesizer and automation providers that facilitate scalable, consistent oligonucleotide manufacturing across laboratory, pilot, and GMP settings.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Oligonucleotide Therapeutics Market, by Molecule
In 2024, nusinersen (SPINRAZA) was the leading segment in the oligonucleotide therapeutics market. The drug was approved in 2016 for spinal muscular atrophy (SMA) and is very well known among prescribers. It also benefits from established reimbursement in several major markets. Due to these factors, demand remains steady despite the availability of newer therapeutics in the market. Notably, Biogen announced that SPINRAZA generated approximately USD 1.5 billion in global revenue in 2024.
Oligonucleotide Therapeutics Market, by Disease type
Neurological disorders held the largest share in the oligonucleotide therapeutics market in 2024. This is mainly because many of the initial oligonucleotide drugs were developed for neurology. Additionally, they are increasingly used to meet long-term treatment needs and specialist-driven care pathways. Examples include SMA and hereditary transthyretin amyloidosis with polyneuropathy, which reflect strong commercial demand for ASO and siRNA treatments.
Oligonucleotide Therapeutics Market, by Route of Administration
In 2024, subcutaneous delivery accounted for the largest share in the oligonucleotide therapeutics market. Many leading siRNA and antisense therapies are designed for subcutaneous dosing because it is practical for repeated treatment and easier to scale in real-world care. This administration also supports patient-friendly dosing in outpatient settings, reducing reliance on infusion centers. As more GalNAc-conjugated, liver-targeted oligonucleotide drugs gain prominence, the preference for subcutaneous dosing continues to grow.
REGION
North America is expected to be the fastest-growing region in the global oligonucleotide therapeutics market during the forecast period
North America is the fastest-growing region in the oligonucleotide therapeutics market, driven by the presence of a large number of RNA drug developers, adequate funding, and extensive clinical trial activities leading to sustained demand for GMP-grade ASOs and siRNAs at preclinical, clinical, and commercial stages. The region also enjoys a fully developed ecosystem of CDMOs, analytical labs, and regulatory knowledge, which are instrumental in getting programs scaled and smoothly transitioned to late-stage supply.
OLIGONUCLEOTIDE THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX
Biogen (Star) is a key demand driver for oligonucleotide therapeutics globally. Its portfolio includes QALSODY (tofersen), an antisense oligonucleotide approved in the US. The company has also developed long-term expertise in antisense programs through its collaboration with Ionis, including SPINRAZA. Astellas Pharma Inc. (Emerging Leader) is also gaining momentum in the oligonucleotide therapeutics market. The company acquired IVERIC Bio and its oligo-based drug.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Biogen (US)
- Alnylam Pharmaceuticals, Inc. (US)
- Sarepta Therapeutics, Inc. (US)
- Astellas, Pharma Inc. (US)
- Jazz Pharmaceuticals Plc (Ireland)
- Nippon Shinyaku, Co., Ltd.
- Ionis Pharmaceuticals, Inc. (US)
- Azenta US Inc. (US)
- Novartis AG (Switzerland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 5.92 BN |
| Market Forecast in 2030 (Value) | USD 17.70 BN |
| Growth Rate | CAGR of 19.7% from 2025–2030 |
| Years Considered | 2023–2030 |
| Base Year | 2024 |
| Forecast Period | 2025–2030 |
| Units Considered | Value (USD MN/BN) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: OLIGONUCLEOTIDE THERAPEUTICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Oligo CDMO aiming to expand US-based commercial contracts |
|
|
RECENT DEVELOPMENTS
- March 2025 : Alnylam received extended US FDA approval for AMVUTTRA (Vutrisiran) to treat the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This approval will help the firm build on treatment approaches to reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits.
- February 2025 : Biogen Inc. and Stoke Therapeutics, Inc. collaborated for the development & commercialization of Zorevunersen. This investigational antisense oligonucleotide (ASO) targets the SCN1A gene for treating Dravet syndrome.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the europe oligonucleotide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Industry Association of Synthetic Biology (IASB), Biotechnology Innovation Organization (BIO), and Genome Canada. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate & validate the total size of the europe oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Oligonucleotide synthesis is the chemical process of creating nucleic acid fragments with specific chemical structures or sequences of varying sizes to form a desired product. These fragments, known as oligonucleotides, have several applications in medical & life science research. They can be used for DNA sequencing and amplification, detecting complementary DNA or RNA through hybridization, creating artificial genes, and introducing targeted genetic mutations.
Oligonucleotides are also used to develop therapeutic drugs. These drugs are produced chemically and have different mechanisms of action, such as interfering with gene expression, blocking the production of harmful proteins, or restoring the function of mutated genes.
Stakeholders
- Pharmaceutical & biotechnology companies
- Hospitals
- Diagnostic laboratories
- Academic researchers and government research organizations
- Private research institutes
- Custom oligonucleotide service providers
- Contract manufacturing organizations (CMOs)
- Oligonucleotide equipment manufacturers
- Contract research organizations (CROs)
- Market research & consulting firms
- Venture capitalists
Report Objectives
- To define, describe, and forecast the europe oligonucleotide synthesis market based on the product, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall europe oligonucleotide synthesis market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the europe oligonucleotide synthesis market.
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the europe oligonucleotide synthesis market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Therapeutics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Oligonucleotide Therapeutics Market